TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Definium Therapeutics reported that DT120, an investigational orally disintegrating LSD tablet, met primary endpoints in Phase III trials for generalized anxiety disorder and major depressive disorder. The company reported symptom improvements versus placebo, but the results were presented at a conference and the drug is not established as an approved treatment.
Definium Therapeutics reported that its investigational orally disintegrating LSD tablet, DT120, met the primary endpoints in two Phase III trials involving people with generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company said symptom improvements compared with placebo emerged within a week and remained evident through 12 weeks; the results were presented at the Neuroscience Education Institute Fall Congress in Colorado Springs.
In the 214-participant Voyage trial for GAD, participants received a single supervised 100-microgram dose of DT120 or placebo. The DT120 group’s Hamilton Anxiety Rating Scale score fell by an average of 11.6 points from baseline at week 12. The placebo-adjusted difference at that point was 5.4 points, with a reported P value below 0.0001. A significant difference was reported by week 1, when the change from baseline in the DT120 group was 11.9 points and the difference from placebo was 7.7 points.
In the 149-participant Emerge trial for MDD, the primary measure was the Montgomery-Åsberg Depression Rating Scale. Definium reported an 8.1-point placebo-adjusted improvement at week 6 and a 7.3-point difference at week 12; both results had P values below 0.0001. At week 1, the mean reduction from baseline in the DT120 group was 17.6 points, a 14.2-point difference from placebo, according to the report. These are trial findings reported by the developer and presented at the meeting.
The trials also reported higher response and remission rates in DT120 groups than in placebo groups. In Voyage, at week 12, 43% of DT120 participants met the response threshold, compared with 16% receiving placebo; remission rates were 14% and 4%, respectively. In Emerge, week 6 response rates were 35% versus 7%, and remission rates were 24% versus 3%. Response and remission were defined using the respective trial rating scales.
A Single Supervised Treatment Day
The findings may matter to patients and clinicians because DT120 is being studied as a single supervised dose, rather than a daily medication regimen. The reported difference from placebo was still present at week 12 in both studies, which suggests a potential longer-lasting effect after one dosing session. That possibility remains a research finding, not evidence that the treatment will be approved or work similarly for every patient.
The approach also involves a substantial clinical setting component. Participants took DT120 during supervised sessions and were monitored until meeting discharge criteria. Average clearance time was 6.4 hours in Voyage and 5.8 hours in Emerge; the report said 90% and 100%, respectively, met criteria by hour eight. If further evidence supports the results, the time and staffing required for a supervised session could shape how the treatment is delivered and who can access it.
Definium chief medical officer Dan Karlin described the findings as a possible option for people who have lived with symptoms for years. That is the company’s interpretation. The trials’ placebo comparisons and reported scale changes provide the current evidence, while independent review, full publication and longer-term follow-up will be needed to clarify the results’ clinical meaning.
Products Worth Considering
Withings Sleep Under-Mattress Sleep Tracking Pad
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
Levoit Vital 100S-P Air Purifier with Washable Pre-Filter
As an affiliate, we earn on qualifying purchases.
What Voyage and Emerge Tested
Voyage enrolled people with GAD whose average starting Hamilton Anxiety Rating Scale score was 27.9; eligibility required a score of at least 20. Participants had an average age of 42, 64% were female, and more than a third had tried at least two prior GAD medications. Emerge enrolled people with active depressive episodes lasting from eight weeks to 24 months. Their average starting MADRS score was 34.5, and 53% had previously received at least two antidepressants.
Both studies compared DT120 with placebo and followed participants through a 12-week double-blind phase. The report said benefits were seen across subgroups, including participants who had tried multiple prior medications. That does not establish how DT120 would compare with existing treatments in direct head-to-head trials, which were not described in the supplied report.
The trials were presented at the NEI Fall Congress. The available account gives selected outcomes and safety findings, but does not provide full study protocols or peer-reviewed papers. The findings therefore should be read as reported Phase III results rather than a complete assessment of the evidence.
“Seeing a clinically meaningful improvement in patients with this level and duration of disease gives us hope that DT120 could offer a new treatment option for people who have been suffering for years and are still in need of better outcomes.”
— Dan Karlin, chief medical officer of Definium Therapeutics, speaking to MedPage Today
Safety and Approval Questions Remain
The reported safety findings are limited to the trial periods and the details provided in the meeting account. In Voyage, the company reported no serious adverse events, suicidality signals or self-injurious behaviors; one participant stopped DT120 because of a treatment-emergent adverse event. In Emerge, no serious adverse events or suicidal behaviors were reported, and no participant discontinued because of an adverse event. Most reported adverse events were mild to moderate, with illusion, nausea and euphoric mood commonly reported on dosing day and headache afterward.
The source material does not provide full adverse-event tables, detailed results for every endpoint, or longer-term safety follow-up. It also does not establish how durable any benefit may be beyond 12 weeks, how the treatment performs against active medicines, or whether results will be replicated in further research. The trials’ reported scores and statistical significance do not by themselves establish the treatment’s overall benefit-risk profile.
Regulatory status is also unresolved. DT120 is described as investigational, and the supplied report does not say that it has been approved or specify a regulatory filing or decision timeline. Patients should not treat these trial results as a recommendation to use LSD; medical decisions should be discussed with a qualified health professional.
Publication and Regulatory Milestones
The immediate next step for readers seeking more detail is the release of fuller trial data, including complete methods, outcome tables and safety results. The supplied report does not state when those materials will appear or identify a planned regulatory submission. Definium’s next public updates, any peer-reviewed publication and regulator announcements would clarify whether the company intends to seek approval and what additional evidence may be required.
Until those details emerge, the confirmed development is limited to the company’s report that DT120 met primary endpoints in two Phase III studies and to the results presented at the NEI congress. The drug remains investigational; further evidence and regulatory review would be needed before any decision about availability for patients.
Key Questions
What is DT120?
DT120 is an investigational orally disintegrating tablet formulation of lysergide, also known as LSD, studied as a single supervised dose in Phase III trials for GAD and MDD.
What did the Phase III trials report?
Definium said DT120 met the primary endpoints in both trials. It reported placebo-adjusted improvements on anxiety and depression rating scales at the main assessment points, with differences also reported at week 12.
Is DT120 approved for anxiety or depression?
The supplied report describes DT120 as investigational and does not report an approval. The trial results do not mean it is available as an approved treatment.
What side effects were reported?
The report lists illusion, nausea and euphoric mood among common adverse events on dosing day, and headache afterward. Most reported events were described as mild to moderate, but complete safety data and longer-term follow-up were not included in the source account.
How long were participants followed?
The reported double-blind phases ran for 12 weeks. The source material does not provide evidence about how long benefits or safety outcomes may persist beyond that period.
Source: medpagetoday.com
